Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2025 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments

– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 – – Announced initiation of pivotal Phase 3 DME program...
November 03, 2025 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...
October 29, 2025 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025

WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...
October 16, 2025 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
October 14, 2025 22:43 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Announces Pricing of Public Offering

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...
October 14, 2025 16:35 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Announces Proposed Public Offering of Common Stock

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...
October 14, 2025 16:01 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema

– DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 – – New...
September 16, 2025 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
August 26, 2025 07:00 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...
August 18, 2025 16:01 ET | Source: EyePoint Pharmaceuticals, Inc.

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...